Full-Time

Field Account Manager

Posted on 12/13/2025

Sartorius

Sartorius

5,001-10,000 employees

Laboratory instruments and bioprocess solutions

No salary listed

Ahmedabad, Gujarat, India

In Person

Must travel frequently; field-based role in Ahmedabad.

Category
Sales & Account Management (2)
,
Requirements
  • Academic degree in life sciences or engineering (higher level of education would be beneficial)
  • Minimum 3 years field sales experience, with preferable laboratory / process based experience in Life Science
  • Hands-on knowledge and proactive usage of SFDC and other CRM tools
  • Excellent communication and negotiation skills
  • Self-motivated, energetic, results oriented, capacity to work independently with a strong sense of responsibility
  • Good teamwork skills and proven ability to also work with cross-functional teams
  • Willingness and ability to travel frequently
  • Proven software skills, e.g. Microsoft Office
Responsibilities
  • Promote the organization's products and services within an assigned geographic area, product range or key account to achieve sales and revenue targets
  • Identify new business opportunities aligned with the organization's overall market and growth strategy
  • Actively use SFDC to manage and document leads and opportunities, all customer interactions and sales activities ensuring that all customer and opportunity information is up-to-date and accurately entered in the CRM system
  • Analyze SFDC data for assigned customers to identify trends, generate customer insights and track sales performance
  • Actively drive newly launched innovative products and services into the marketplace and proactively follow up on the successful implementation of sales activity
  • Assess and analyze customer needs, generate leads, respond to customer inquiries and suggest products and services as appropriate
  • Develop and implement account plans and request and coordinate resources in line with the account plans
  • Work closely with cross functional team to create higher market perception and successful strategies to gain business from an account
  • Coordinate and participate in marketing activities in assigned territory
  • Frequently assess the potential of each customer and plan to realize it into business
  • Manage and build strong customer relationships for long term partnership

Sartorius is a global partner in life sciences research and biopharmaceutical manufacturing. It provides laboratories with innovative instruments and consumables for research and quality control, and it offers Bioprocess Solutions focused on single-use systems that help manufacture biotech medicines, vaccines, and cell- and gene- therapies safely, quickly, and cost-effectively. Its products support the full path from drug discovery to commercial manufacturing, with a large worldwide footprint of more than 60 sites and a mission to help more people access better medicines. Sartorius differentiates itself through its broad portfolio spanning lab and bioprocess needs, a strong emphasis on single-use technologies, continuous portfolio expansion via acquisitions, and deep expertise serving pharmaceutical, biotech, and academic customers. Its goal is to simplify progress from research and development to scalable manufacturing so that life-saving medicines can reach patients worldwide.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Simplify Jobs

Simplify's Take

What believers are saying

  • Order intake hit highest Q4 2025 level, book-to-bill above one.
  • Equity ratio reached 48.7% after €1B capital increase in 2024.
  • 6-10% sales growth projected for 2026 with margins above 30%.

What critics are saying

  • Trump tariffs hit German imports; US manufacturing lags by 2027.
  • Danaher's Cytiva bundling steals share from Sartorius platforms.
  • Biotech funding drop 36% in 2024 cuts customer equipment capex.

What makes Sartorius unique

  • Sartorius leads in single-use ultrafilters like Sartocon Slice 50.
  • Ann Arbor $100M Center of Excellence boosts bioanalytics innovation.
  • SIMCA-online software excels in batch process monitoring.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Flexible Work Hours

Wellness Program

Professional Development Budget

Company News

The Associated Press
Mar 16th, 2026
Sartorius launches platform to cut CAR-T manufacturing costs by 90% and quadruple output

Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.

Yahoo Finance
Feb 3rd, 2026
Sartorius grows revenue 7.6% to €3.5B with EBITDA margin expanding to 29.7%

Sartorius AG reported strong Q4 2025 results, with revenue growing 7.6% in constant currencies to over €3.5 billion, exceeding full-year guidance. The company's EBITDA margin expanded 170 basis points to 29.7%, whilst underlying net profit increased 18%. The bioprocess solutions division drove growth with 9.5% revenue increase in constant currency, supported by strong double-digit growth in recurring revenue. However, the lab products and services division remained essentially flat at 0.2% growth, facing challenges from unfavorable product mix. Sartorius improved its net debt to EBITDA ratio from 3.96 times to 3.55 times, demonstrating financial discipline. The company set a broad guidance range for 2026, citing macroeconomic volatility. Management noted that US onshoring initiatives are expected to impact revenue from 2027 onwards rather than 2026.

Yahoo Finance
Feb 3rd, 2026
Sartorius Stedim Biotech posts 18% profit growth despite equipment softness, cuts debt ratio to 3.55

Sartorius Stedim Biotech reported strong profit growth for Q4 2025, with revenue increasing 7.6% in constant currencies to over €3.5 billion. The EBITDA margin improved 170 basis points to 29.7%, whilst underlying net profit surged 18%. The bioprocess solutions division led growth at 9.5% in constant currency, driven by double-digit growth in recurring revenue that offset continued equipment softness. Order intake grew faster than sales, with the book-to-bill ratio remaining above one. Free cash flow reached €390 million, though operating cash flow declined to €837 million from €976 million previously. The net debt-to-EBITDA ratio improved from 3.96 to 3.55 times. However, the company faces headwinds from a weaker US dollar and set broad 2026 guidance due to market volatility.

Firmenpresse
Sep 16th, 2025
Repairon secures funding for heart therapy

Repairon GmbH, a German biotech company, has secured a substantial Series A funding for its innovative "heart patch" therapy aimed at treating advanced heart failure. The funding, led by Bioventure Management GmbH and co-invested by Satorius AG, will support the Phase 3 trial and GMP production scaling. The heart patch, made from engineered heart muscle, is applied to damaged heart tissue to restore function. Positive preclinical and Phase 1/2 results were published in Nature.

IT Juzi
Aug 12th, 2025
Nanotein secures $3M strategic investment

Nanotein, a cell therapy developer, has secured a $3 million strategic investment from Sartorius Stedim Biotech.

INACTIVE